1452 related articles for article (PubMed ID: 26510911)
1. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
[TBL] [Abstract][Full Text] [Related]
5. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
6. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
8. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
11. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
12. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
13. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
14. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
15. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
16. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
17. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L
Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
[TBL] [Abstract][Full Text] [Related]
19. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
20. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
